{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:44:20Z","timestamp":1790315060833,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diffuse malignant peritoneal mesothelioma (PM) is a rare neoplasm, traditionally associated with a poor prognosis. There are other varieties of PM that are even less frequent and of uncertain malignancy. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved prolonged survival in selected patients. The aim of this study is to analyze the patients with PM assessed in our center. Clinicopathological characteristics, diagnostic procedures and survival results from patients with PM appraised at our unit, according to the applied treatment, were analyzed. Seventeen patients were assessed between 2007 and 2019. Three cases had multicystic PM that were treated with complete CRS + HIPEC; all patients are alive and free of disease after a long follow-up. Three other cases had biphasic PM; a curative treatment could be performed in none of them, and their survival was minimal (&lt;6 moths). Lastly, 11 cases with epithelioid PM were treated. Two cases were considered unresectable at laparoscopy (PCI 39); one of them had a long survival (67 months) with three iterative laparoscopic palliatives HIPECs for refractory ascites. The other nine cases were treated with curative CRS + HIPEC, with a median PCI of 14 (range 4\u201325), and a median overall survival (OS) of 58 months, with a 5-year OS of 47.4%. In conclusion, CRS + HIPEC, when possible, appears to be the optimal treatment for patients with PM. Knowledge of this therapeutic option is crucial, both to offer it to patients and to avoid delays in their referral to appropriate centers for treatment.<\/jats:p>","DOI":"10.3390\/jcm12062288","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T02:40:11Z","timestamp":1678934411000},"page":"2288","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peritoneal Mesothelioma in a High Volume Peritoneal Surface Malignancies Unit"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-5112","authenticated-orcid":false,"given":"Fernando","family":"Pereira","sequence":"first","affiliation":[{"name":"Peritoneal Surface Malignancies Unit, Department of Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Faculty of Health Sciences, School of Medicine, Universidad Rey Juan Carlos, 28933 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Pereira","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, School of Medicine, Universidad Rey Juan Carlos, 28933 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-1740","authenticated-orcid":false,"given":"Israel","family":"Manzanedo","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancies Unit, Department of Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Faculty of Health Sciences, School of Medicine, Universidad Rey Juan Carlos, 28933 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Serrano","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancies Unit, Department of Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Faculty of Health Sciences, School of Medicine, Universidad Rey Juan Carlos, 28933 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibalitz","family":"P\u00e9rez-Viejo","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancies Unit, Department of Surgery, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain"},{"name":"Faculty of Health Sciences, School of Medicine, Universidad Rey Juan Carlos, 28933 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: A review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973\u20132005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jso.21055","article-title":"Consensus statement on peritoneal mesothelioma","volume":"98","author":"Deraco","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program","volume":"7","author":"Janne","year":"2005","journal-title":"Clin. Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal mesothelioma","volume":"9","author":"Greenbaum","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","article-title":"Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients","volume":"100","author":"Valle","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-012-2360-0","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy: Indications, aims, and results: A systematic review of the literature","volume":"19","author":"Facchiano","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1245\/s10434-018-07153-2","article-title":"Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry","volume":"26","author":"Vogin","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Noiret, B., Renaud, F., Piessen, G., and Eveno, C. (2019). Multicystic peritoneal mesothelioma: A systematic review of the literature. Pleura Peritoneum, 4.","DOI":"10.1515\/pp-2019-0024"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","article-title":"Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival","volume":"43","author":"Sugarbaker","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0009-739X(07)71268-X","article-title":"Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: Cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia","volume":"81","author":"Cendoya","year":"2007","journal-title":"Cir. Esp."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: A systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s13193-015-0486-9","article-title":"Diagnostic Laparoscopy in the Pre-operative Assessment of Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancies","volume":"7","author":"Seshadri","year":"2016","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/bjs.10723","article-title":"Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE)","volume":"105","author":"Passot","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","article-title":"Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality","volume":"249","author":"Chua","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","article-title":"Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study","volume":"25","author":"Malgras","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","article-title":"The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Deraco","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1245\/s10434-017-6033-x","article-title":"Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy","volume":"24","author":"Gelli","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","article-title":"Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20190010","DOI":"10.1515\/pp-2019-0010","article-title":"MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma","volume":"4","author":"Sgarbura","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1245\/s10434-017-6293-5","article-title":"Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry","volume":"25","author":"Votanopoulos","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:55:56Z","timestamp":1760122556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12062288"],"URL":"https:\/\/doi.org\/10.3390\/jcm12062288","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}